Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up

BACKGROUND: The treatment landscape of metastatic renal cell carcinoma (mRCC) has substantially advanced over the last three decades, whereby data from controlled clinical trials indicate significant improvements regarding patients’ overall survival (OS) in highly selected patient cohorts. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fluhrer, Hannah, Hutterer, Georg C., Golbeck, Sylvia, Stidl, Michael, Niedrist, Tobias, Pichler, Renate, Mischinger, Johannes, Seles, Maximilian, Mannweiler, Sebastian, Spiegelberg, Jasmin, Bauernhofer, Thomas, Jost, Philipp J., Ahyai, Sascha, Zigeuner, Richard, Pichler, Martin, Barth, Dominik A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679616/
https://www.ncbi.nlm.nih.gov/pubmed/36425872
http://dx.doi.org/10.1177/17588359221134065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679616/
https://www.ncbi.nlm.nih.gov/pubmed/36425872
http://dx.doi.org/10.1177/17588359221134065

Ejemplares similares